ACRV ▼ -1.1% - Acrivon Therapeutics, Inc. $ACRV - Acrivon Announces Late-Breaking Oral Plenary Presentation of Early Phase 1/2 Clinical Results in AP3-Predicted Tumors for its First-in-Class WEE1/PKMYT1 Inhibitor ACR-2316 at the 38th EORTC-NCI-AACR Symposium 29-OCT-2026 08:00 AM ET